Introduction and expression of PIK3CA E545K in a papillary thyroid cancer BRAF V600E cell line leads to a dedifferentiated aggressive phenotype

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1916-0216

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Introduction and expression of PIK3CA E545K in a papillary thyroid cancer BRAF V600E cell line leads to a dedifferentiated aggressive phenotype ; volume:51 ; number:1 ; day:22 ; month:2 ; year:2022 ; pages:1-10 ; date:12.2022
Journal of otolaryngology, head & neck surgery ; 51, Heft 1 (22.2.2022), 1-10, 12.2022

Creator: Pinto, Nicole
Ruicci, Kara M.
Khan, Mohammed Imran
Shaikh, Mushfiq Hassan
Zeng, Yu Fan Peter
Yoo, John
Fung, Kevin
MacNeil, S. Danielle
Mendez, Adrian
Mymryk, Joe S.
Barrett, John W.
Boutros, Paul C.
Nichols, Anthony C.

Contributor: SpringerLink (Online service)

DOI: 10.1186/s40463-022-00558-w

URN: urn:nbn:de:101:1-2022052420522835927065

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Pinto, Nicole
Ruicci, Kara M.
Khan, Mohammed Imran
Shaikh, Mushfiq Hassan
Zeng, Yu Fan Peter
Yoo, John
Fung, Kevin
MacNeil, S. Danielle
Mendez, Adrian
Mymryk, Joe S.
Barrett, John W.
Boutros, Paul C.
Nichols, Anthony C.
SpringerLink (Online service)

Other Objects (12)

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma

Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study

Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma

Hochschulschrift

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma

Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study

Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma

Hochschulschrift

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma

Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study

Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma

Hochschulschrift

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Introduction and expression of PIK3CA E545K in a papillary thyroid cancer BRAF V600E cell line leads to a dedifferentiated aggressive phenotype

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma

Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study

Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma

Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study

Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma

Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study

Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature

Related objects

Reset password